Lead Product(s): Nemonoxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Taigexyn
Highest Development Status: Approved Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 30, 2020
Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs.